Afstyla

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
25-07-2022
Tabia za bidhaa Tabia za bidhaa (SPC)
25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma (PAR)
30-03-2017

Viambatanisho vya kazi:

lonoctocog alfa

Inapatikana kutoka:

CSL Behring GmbH

ATC kanuni:

B02BD02

INN (Jina la Kimataifa):

lonoctocog alfa

Kundi la matibabu:

Antihemorrhagics

Eneo la matibabu:

Hemophilia A

Matibabu dalili:

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Afstyla can be used for all age groups.

Bidhaa muhtasari:

Revision: 10

Idhini hali ya:

Authorised

Idhini ya tarehe:

2017-01-04

Taarifa za kipeperushi

                                44
B. PACKAGE LEAFLET
45
PACKAGE LEAFLET: INFORMATION FOR THE USER
AFSTYLA 250 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
AFSTYLA 500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
AFSTYLA 1000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
AFSTYLA 1500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
AFSTYLA 2000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
AFSTYLA 2500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
AFSTYLA 3000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
lonoctocog alfa (recombinant, single-chain coagulation factor VIII)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD START
USING THIS MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have further questions, ask your doctor, pharmacist or nurse.
•
This medicine has been prescribed for you
OR YOUR CHILD
only. Do not pass it on to others. It
may harm them, even if their signs of illness are the same as yours.
•
If you get any side effects talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What AFSTYLA is and what it is used for
2.
What you need to know before you
OR YOUR CHILD
use AFSTYLA
3.
How to use AFSTYLA
4.
Possible side effects
5.
How to store AFSTYLA
6.
Contents of the pack and other information
1.
WHAT AFSTYLA IS AND WHAT IT IS USED FOR
AFSTYLA is a human clotting (coagulation) factor VIII product that is
produced by recombinant
DNA technology. The active substance in AFSTYLA is lonoctocog alfa.
AFSTYLA is used to treat and prevent bleeding episodes in patients
with haemophilia A (inborn factor
VIII deficiency). Factor VIII is a protein needed for blood to clot.
Patients with haemophilia A lack
this factor, so blood does not clot as quickly as it should and they
have an increased tendency to bleed.
AFSTYLA works by replacing the missing factor VIII in haemophilia A
patients enabling their blood
to clot normally.
AFSTYLA can be 
                                
                                Soma hati kamili

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
AFSTYLA 250 IU powder and solvent for solution for injection
AFSTYLA 500 IU powder and solvent for solution for injection
AFSTYLA 1000 IU powder and solvent for solution for injection
AFSTYLA 1500 IU powder and solvent for solution for injection
AFSTYLA 2000 IU powder and solvent for solution for injection
AFSTYLA 2500 IU powder and solvent for solution for injection
AFSTYLA 3000 IU powder and solvent for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
AFSTYLA 250 IU powder and solvent for solution for injection
Each vial contains nominally 250 IU recombinant, single-chain
coagulation factor VIII
_ _
(rVIII-
SingleChain, INN = lonoctocog alfa). After reconstitution with 2.5 ml
water for injections the
solution contains 100 IU/ml of rVIII-SingleChain.
AFSTYLA 500 IU powder and solvent for solution for injection
Each vial contains nominally 500 IU recombinant, single-chain
coagulation factor VIII
_ _
(rVIII-
SingleChain, INN = lonoctocog alfa). After reconstitution with 2.5 ml
water for injections the
solution contains 200 IU/ml of rVIII-SingleChain.
AFSTYLA 1000 IU powder and solvent for solution for injection
Each vial contains nominally 1000 IU recombinant, single-chain
coagulation factor VIII
_ _
(rVIII-
SingleChain, INN = lonoctocog alfa). After reconstitution with 2.5 ml
water for injections the
solution contains 400 IU/ml of rVIII-SingleChain.
AFSTYLA 1500 IU powder and solvent for solution for injection
Each vial contains nominally 1500 IU recombinant, single-chain
coagulation factor VIII
_ _
(rVIII-
SingleChain, INN = lonoctocog alfa). When reconstituted with 5 ml
water for injections the
solution contains 300 IU/ml of rVIII-SingleChain.
AFSTYLA 2000 IU powder and solvent for solution for injection
Each vial contains nominally 2000 IU recombinant, single-chain
coagulation factor VIII
_ _
(rVIII-
SingleChain, INN = lonoctocog alfa). When reconstituted with 5 ml
water for injections the
solution contains 400 IU
                                
                                Soma hati kamili

Bidhaa zinazofanana

Viambatanisho vya kazi lonoctocog alfa

lonoctocog alfa

ATC kanuni B02BD02

B02BD02

Mzalishaji au wazalishaji wadogowadogo CSL Behring GmbH

CSL Behring GmbH

INN (Jina la Kimataifa) lonoctocog alfa

lonoctocog alfa

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kibulgaria 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kihispania 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kicheki 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kidenmaki 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kijerumani 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kiestonia 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kigiriki 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kifaransa 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kiitaliano 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kilatvia 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kilithuania 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kihungari 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kimalta 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kiholanzi 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kipolandi 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kireno 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kiromania 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kislovakia 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kislovenia 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kifinlandi 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kiswidi 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 30-03-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kinorwe 25-07-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 25-07-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 25-07-2022
Tabia za bidhaa Tabia za bidhaa Kroeshia 25-07-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 30-03-2017

Tafuta arifu zinazohusiana na bidhaa hii

Taadhari Afstyla lonoctocog alfa

Afstyla lonoctocog alfa

Tazama historia ya hati

Historia ya nyaraka Historia ya nyaraka

Afstyla